ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-OR105

Prevention of Proteinuria by a Novel, Subnanomolar ApoL1 Inhibitor

Session Information

Category: Glomerular Diseases

  • 1403 Podocyte Biology


  • Antonio, Brett M., OmniAb, Durham, North Carolina, United States
  • Zahler, Nathan, OmniAb, Durham, North Carolina, United States
  • Mechin, Ingrid, OmniAb, Durham, North Carolina, United States
  • Theile, Jonathan W., OmniAb, Durham, North Carolina, United States
  • Dow, Robert L., BioPharmaWorks, Groton, Connecticut, United States
  • Volkmann, Robert A., BioPharmaWorks, Groton, Connecticut, United States
  • Zellmer, Shannon Gail, OmniAb, Durham, North Carolina, United States
  • Chdid, Lhoucine, OmniAb, Durham, North Carolina, United States
  • Nair, Anil, OmniAb, Durham, North Carolina, United States
  • Krafte, Douglas, OmniAb, Durham, North Carolina, United States

Genetic variants of human ApoL1, which have arisen under evolutionary pressure to target mutant trypanosomes, have also been associated with an increased risk of developing chronic kidney diseases (CKD) in people of African ancestry1. Recently reported clinical results suggest inhibition of ApoL1 ion channel function may produce clinical benefit in patients with ApoL1-induced nephropathies2.
1. doi: 10.2215/CJN.15161219
2. doi: 10.1056/NEJMoa2202396


We established stable HEK-TREx cell lines in the EIK haplotype expressing human G1 and G2 variants under control of an inducible promoter and identified compounds for evaluation via high throughput screening, in silico profiling and medicinal chemistry design.
Tl+ flux and electrophysiology assays were used to assess in vitro efficacy of compounds against ApoL1 function. A human transgenic mouse model expressing ApoL1-G1 EIK and exhibiting a significantly elevated urinary albumin/creatine ratio (uACR) following IFNγ challenge was used to assess in vivo efficacy. Compound efficacy was determined by assessing inhibition of proteinuria.


Our lead compound, ICA-264 demonstrated concentration-dependent inhibition of ApoL1-G1 mediated Tl+ flux with an IC50 value of 4 nM (95% CI 3.5-4.4 nM, n=196). The potency was similar against ApoL1-G2 (IC50 = 5 nM, 95% CI 4.4-6.0 nM, n=77). Directly measuring ApoL1 current in electrophysiological experiments demonstrated potent inhibition with IC50 values at -80 mV and +60 mV of 0.6 nM and 0.4 nM (95% CI 0.35-0.47 and 0.49-0.65, respectively). Analogs of ICA-264 were identified with IC50 values as low as 0.26 nM in electrophysiological assays. In our in vivo model oral dosing of ICA-264 (BID) at 3, 10, and 30 mg/kg decreased the IFNγ-induced rise in uACR by 73%, 92%, and 91%, respectively (n=6) on day 2.


ICA-264 is a novel ApoL1 inhibitor with excellent drug-like properties and in vivo efficacy. This merits further consideration as a potential novel therapeutic for the treatment of ApoL1-induced nephropathies.


  • Commercial Support – OmniAb, Inc.